Predictors and early markers of response to biological therapies in inflammatory bowel diseases

Giuseppe Privitera, Daniela Pugliese, Gian Ludovico Rapaccini, Antonio Gasbarrini, Alessandro Armuzzi, Luisa Guidi

Risultato della ricerca: Contributo in rivistaArticolo in rivista


Inflammatory bowel diseases (IBD) are chronic conditions that primarily affect the gas-trointestinal tract, with a complex pathogenesis; they are characterized by a significant heterogene-ity of clinical presentations and of inflammatory pathways that sustain intestinal damage. After the introduction of the first biological therapies, the pipeline of therapies for IBD has been constantly expanding, and a significant number of new molecules is expected in the next few years. Evidence from clinical trials and real-life experiences has taught us that up to 40% of patients do not respond to a specific drug. Unfortunately, to date, clinicians lack a valid tool that can predict each patient’s response to therapies and that could help them in choosing what drug to administer. Several candidate biomarkers have been investigated so far, with conflicting results: clinical, genetic, immuno-logical, pharmacokinetic and microbial markers have been tested, but no ideal marker has been identified so far. Based on recent evidence, multiparametric models seemingly hold the greatest potential for predicting response to therapy. In this narrative review, we aim to summarize the current knowledge on predictors and early markers of response to biological therapies in IBD.
Lingua originaleEnglish
pagine (da-a)1-21
Numero di pagine21
RivistaJournal of Clinical Medicine
Stato di pubblicazionePubblicato - 2021


  • Biological therapy
  • Biomarkers
  • Inflammatory bowel disease
  • Predictors


Entra nei temi di ricerca di 'Predictors and early markers of response to biological therapies in inflammatory bowel diseases'. Insieme formano una fingerprint unica.

Cita questo